We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+5.66%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$80.1B
AUM Growth
+$9.71B
(+14%)
Cap. Flow
+$17.3B
Cap. Flow
% of AUM
21.56%
Top 10 Holdings %
Top 10 Hldgs %
29.43%
Holding
1,430
New
62
Increased
858
Reduced
440
Closed
53
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$13B |
| 2 |
NVIDIA
NVDA
|
+$468M |
| 3 |
ASML
ASML
|
+$424M |
| 4 |
Applied Materials
AMAT
|
+$310M |
| 5 |
Qualcomm
QCOM
|
+$307M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kinross Gold
KGC
|
+$444M |
| 2 |
Tyler Technologies
TYL
|
+$256M |
| 3 |
C.H. Robinson
CHRW
|
+$251M |
| 4 |
Philip Morris
PM
|
+$245M |
| 5 |
RTX Corp
RTX
|
+$234M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 40.76% |
| 2 | Materials | 26.89% |
| 3 | Healthcare | 7.04% |
| 4 | Industrials | 6.5% |
| 5 | Financials | 5.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CIM
451
Chimera Investment
CIM
$1.05B
| $9.88M | 0.01% |
645,480
-39,093
| -6% | -$585K |
|
452
PACCAR
PCAR
$69.6B
| $9.81M | 0.01% |
94,494
+9,370
| +11% | +$916K |
|
|
EU
453
enCore Energy
EU
$223M
| $9.76M | 0.01% |
2,434,342
+1,148,056
| +89% | +$4.25M |
|
454
Neurocrine Biosciences
NBIX
$16.9B
| $9.62M | 0.01% |
83,582
-12,637
| -13% | -$1.73M |
|
455
Charles River Laboratories
CRL
$11.1B
| $9.57M | 0.01% |
51,273
-6,633
| -11% | -$1.38M |
|
456
State Street Energy Select Sector SPDR ETF
XLE
$37.9B
| $9.55M | 0.01% |
212,726
-422
| -0.2% | -$18.9K |
|
|
EXAS
457
DELISTED
Exact Sciences
EXAS
| $9.55M | 0.01% |
135,865
-17,484
| -11% | -$987K |
|
|
TWO
458
Two Harbors Investment
TWO
$1.27B
| $9.54M | 0.01% |
743,144
-114,102
| -13% | -$1.56M |
|
|
RC
459
Ready Capital
RC
$278M
| $9.51M | 0.01% |
1,366,040
+23,970
| +2% | +$203K |
|
|
BNY
460
Bank of New York Mellon
BNY
$106B
| $9.49M | 0.01% |
124,258
-19,639
| -14% | -$1.29M |
|
461
Edison International
EIX
$27.4B
| $9.44M | 0.01% |
109,716
-24,294
| -18% | -$1.97M |
|
462
LPL Financial
LPLA
$28.1B
| $9.39M | 0.01% |
36,380
+13,814
| +61% | +$3.11M |
|
463
Toll Brothers
TOL
$14.2B
| $9.34M | 0.01% |
63,589
+18,169
| +40% | +$2.46M |
|
464
ResMed
RMD
$31.5B
| $9.34M | 0.01% |
39,334
+1,121
| +3% | +$250K |
|
465
Donaldson
DCI
$11.2B
| $9.33M | 0.01% |
126,211
+23,927
| +23% | +$1.73M |
|
466
Infosys
INFY
$49.6B
| $9.29M | 0.01% |
418,301
-49,070
| -10% | -$1.07M |
|
|
MFA
467
MFA Financial
MFA
$925M
| $9.26M | 0.01% |
764,393
-58,303
| -7% | -$688K |
|
468
BioMarin Pharmaceuticals
BMRN
$11.6B
| $9.25M | 0.01% |
132,132
-1,390
| -1% | -$116K |
|
469
Veralto
VLTO
$23.1B
| $9.2M | 0.01% |
82,906
+951
| +1% | +$100K |
|
470
Quanta Services
PWR
$103B
| $9.18M | 0.01% |
29,948
+29,611
| +8,787% | +$7.83M |
|
471
Gentex
GNTX
$5.02B
| $9.14M | 0.01% |
309,668
+132,322
| +75% | +$4.11M |
|
472
Insmed
INSM
$21.4B
| $9.14M | 0.01% |
+127,024
| New | +$9.37M |
|
|
DX
473
Dynex Capital
DX
$3.13B
| $9.13M | 0.01% |
724,876
+5,725
| +0.8% | +$70.7K |
|
474
Alexandria Real Estate Equities
ARE
$8.78B
| $9.08M | 0.01% |
75,737
+9,400
| +14% | +$1.12M |
|
475
Mondelez International
MDLZ
$77.9B
| $9.05M | 0.01% |
128,242
-65
| -0.1% | -$4.57K |
|
Similar funds
VanEck Associates's Q3 2024 Portfolio in Review
As of Q3 2024, VanEck Associates held 1,430 positions worth $80.1B, up 14% from $70.4B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
VanEck Associates deployed $17.3B of net new capital in Q3 2024, opening 62 new positions and adding to 858 existing holdings. Its largest new stake was GE HealthCare: 2,335,235 shares worth $209M.
By sector, the portfolio is most concentrated in Technology at 41% of assets, down from 42% a quarter earlier, followed by Materials and Healthcare.
On the sell side, the largest reduction was Kinross Gold, an estimated $444M trimmed.
- VanEck Associates's largest Q3 2024 buy was GE HealthCare: 2,335,235 shares worth $209M.
- VanEck Associates added most to Lam Research in Q3 2024, an estimated $13B increase.
- VanEck Associates's biggest Q3 2024 reduction was Kinross Gold, cutting an estimated $444M.
- VanEck Associates fully exited RBC Bearings Incorporated 5.00% Series A Mandatory Convertible Preferred Stock in Q3 2024, selling an estimated $22.4M.
- VanEck Associates's ten largest holdings make up 29% of its $80.1B portfolio in Q3 2024.
- VanEck Associates opened 62 new positions and closed 53 in Q3 2024.
- VanEck Associates's portfolio value rose 14% quarter-over-quarter to $80.1B.
Based on VanEck Associates's 13F filing for Q3 2024, filed 29 Oct 2024.